Health Information Search Results
Peer Reviewed Scientific Research Reports.
|<< Prev 20 ||Showing 1 to 11 of 11 Matches||Next 20 >>|
1. Evaluation of swallowing disorders in multiple sclerosis.
Match Strength: 8.823
Swallowing disorders are present in more than one-third of multiple sclerosis (MS) patients. Dysphagia in MS usually receives limited attention, maybe because of the unpredictability and variability of the disease among patients. Complications of dysphagia such as dehydration and aspiration pneumonia are a common cause of death and morbidity in late MS. For the effectiveness of swallowing rehabilitation in MS-related dysphagia we suggest that all MS patients should have a thorough evaluation of swallow ability ... Read More »
» Published in Neurol Sci. 2006 Sep;27 Suppl 4:s335-7.
2. New developments in palliative therapy.
Match Strength: 7.955
Over the past 5years, new developments in the palliative treatment of incurable cancer of the oesophagus and gastro-oesophageal junction have been introduced with the aim of palliating dysphagia and improving the survival of patients. Stent placement is currently the most widely used treatment for palliation of dysphagia from oesophageal cancer. A stent offers rapid relief of dysphagia; however, current recurrent dysphagia rates vary between 30 and 40%. Recently introduced new stent designs are likely to reduce recurrent dysphagia by decreasing stent migration and non-tumoral tissue overgrowth ... Read More »
» Published in Best Pract Res Clin Gastroenterol. 2006;20(5):959-78.
3. A novel dysphagia diet improves the nutrient intake of institutionalized elders.
Match Strength: 6.122
OBJECTIVES: Dysphagia affects 35% to 60% of the institutionalized elderly population. This study aimed at evaluating the nutrient intake of frail institutionalized elderly persons with dysphagia and to assess the impact of Sainte-Anne's Hospital Advanced Nutritional Care program on dietary intake and weight. DESIGN: A 12-week intervention study. SUBJECTS/SETTING: Ninety-three individuals residing in a Montreal, Canada, long-term care facility who were aged at least 65 years were evaluated. Seventeen subjects with a body mass index (BMI; calculated as kg/m(2)) <24 or weight loss >7.5% ... Read More »
» Published in J Am Diet Assoc. 2006 Oct;106(10):1614-23.
4. A pilot study of chlorhexidine and benzydamine oral rinses for the prevention and treatment of irradiation mucositis in patients with head and neck cancer.
Match Strength: 5.550
This pilot study was designed to compare the efficacy of 0.2% wt/vol chlorhexidine gluconate and 0.15% wt/vol benzydamine hydrochloride oral rinses in alleviating irradiation oropharyngeal mucositis for patients with head and neck cancer. This was a prospective, randomized, and double-blinded study. Fourteen subjects were stratified based on nasopharyngeal cancer and non-nasopharyngeal head and neck cancer, and were randomly assigned to receive oral care protocol either containing with chlorhexidine (n = 7) or benzydamine (n = 7) from the first day to 2 weeks after the completion of ... Read More »
» Published in Cancer Nurs. 2006 Sep-Oct;29(5):423-30.
5. Botulinum toxin type A treatment for Parkinsonian patients with moderate to severe sialorrhea.
Match Strength: 4.659
PURPOSE: To investigate the effect of botulinum toxin type A (BTX-A; Botox) in reducing saliva in patients with Parkinsonism. METHODS: Fifteen patients with clinical diagnosis of idiopathic Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy were enrolled in this open clinical trial. A total of 40-unit dose of Botox was injected into the bilateral parotid and submandibular glands. Objective measuring of saliva production with dental rods, subjective Drooling Score, personal impression of clinical improvement, and the duration of response were used for the global ... Read More »
» Published in Acta Neurol Taiwan. 2006 Sep;15(3):170-6. Comment in: Acta Neurol Taiwan. 2006 Sep;15(3):151-3.
6. Correlation of gastroesophageal reflux disease symptoms characteristics with long-segment Barrett's esophagus.
Match Strength: 4.547
Thus far, there has been a paucity of studies that have assessed the value of the different gastroesophageal reflux disease (GERD) symptom characteristics in identifying patients with long-segment Barrett's esophagus versus those with short-segment Barrett's esophagus. To determine if any of the symptom characteristics of GERD correlates with long-segment Barrett's esophagus versus short-segment Barrett's esophagus. Patients seen in our Barrett's clinic were prospectively approached and recruited into the study. All patients underwent an endoscopy, validated GERD symptoms questionnaire and a ... Read More »
» Published in Dis Esophagus. 2006;19(5):360-5.
7. Sems (self expanding metal stents) in palliation of esophageal cancer dysphagia.
Match Strength: 4.051
Symptomatic inoperable esophageal carcinoma represents a major clinical problem. With no treatment, swallowing deteriorates with a dramatic worsening of quality of life. At present, self-expanding metal stents (SEMS) are the most effective non surgical palliation in inoperable esophageal cancer. The different types of available SEMS, techniques, results and complications are discussed. Publication Types: ... Read More »
» Published in Rays. 2006 Jan-Mar;31(1):67-71.
8. Biologic prosthesis reduces recurrence after laparoscopic paraesophageal hernia repair: a multicenter, prospective, randomized trial.
Match Strength: 3.991
OBJECTIVE: Laparoscopic paraesophageal hernia repair (LPEHR) is associated with a high recurrence rate. Repair with synthetic mesh lowers recurrence but can cause dysphagia and visceral erosions. This trial was designed to study the value of a biologic prosthesis, small intestinal submucosa (SIS), in LPEHR. METHODS: Patients undergoing LPEHR (n = 108) at 4 institutions were randomized to primary repair -1 degrees (n = 57) or primary repair buttressed with SIS (n = 51) using a standardized technique. The primary outcome measure was evidence of recurrent hernia (> or =2 cm) on UGI, read by a ... Read More »
» Published in Ann Surg. 2006 Oct;244(4):481-90.
9. Giant pleomorphic adenoma of soft palate leading to obstruction of the nasopharyngeal port.
Match Strength: 3.629
Pleomorphic adenoma is the most common tumor of minor salivary glands, but it is rarely located in the soft palate. It is generally a small mass at the time of diagnosis, but if it is neglected it can rarely become larger, leading to obstructive symptoms such as snoring, hypernasal speech, and dysphagia. Surgical removal of the mass is curative. In this paper, we present a case of an unusually large pleomorphic adenoma of the soft palate leading to snoring and hypernasal speech. The defect that resulted from the excision of the mass is covered with a uvular flap. Publication Types: Case ... Read More »
» Published in J Craniofac Surg. 2006 Sep;17(5):1001-4.
10. The adult form of Niemann-Pick disease type C.
Match Strength: 3.404
Niemann-Pick disease type C (NPC) is a fatal neurovisceral lipid storage disease of autosomal inheritance resulting from mutations in either the NPC1 (95% of families) or NPC2 gene. The encoded proteins appear to be involved in lysosomal/late endosomal transport of cholesterol, glycolipids and other molecules but their exact function is still unknown. The clinical spectrum of the disease ranges from a neonatal rapidly fatal disorder to an adult-onset chronic neurodegenerative disease. Based upon a comprehensive study of 13 unrelated adult patients diagnosed in France over the past 20 years as ... Read More »
» Published in Brain. 2007 Jan;130(Pt 1):120-33. Epub 2006 Sep 26.
11. Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment.
Match Strength: 2.454
OBJECTIVE: Gastro-oesophageal reflux disease (GORD) symptoms have a significant impact on patients' well-being. Onset of symptom relief is therefore an important consideration in GORD treatment. The primary objective was to compare the efficacy of rabeprazole (20 mg) and omeprazole (20 mg) regarding onset of heartburn control during the first 7 days of treatment in patients with erosive oesophagitis. Secondary objectives included maintenance of sustained heartburn control, control of other GORD symptoms (e.g. acid regurgitation, epigastric pain, dysphagia), effect on quality of life, patient ... Read More »
» Published in Scand J Gastroenterol. 2006 Oct;41(10):1132-40.
|<< Prev 20 ||Showing results 1 to 11 of 11||Next 20 >>|
* All information on Level1Diet.com is for educational purposes only. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. Before changing your diet, or adding supplements to your diet, or beginning an exercise program, everyone should consult a qualified and licensed health practitioner; a physician, dietician or similar professional.